Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

84.51USD
31 Jul 2015
Change (% chg)

$-0.03 (-0.04%)
Prev Close
$84.54
Open
$84.91
Day's High
$85.25
Day's Low
$84.38
Volume
1,625,835
Avg. Vol
1,470,848
52-wk High
$90.17
52-wk Low
$60.14

LLY.N

Chart for LLY.N

About

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company's products are sold in approximately 120 countries. The Company's human pharmaceutical business segment... (more)

Overall

Beta: 0.31
Market Cap(Mil.): $93,682.76
Shares Outstanding(Mil.): 1,108.54
Dividend: 0.50
Yield (%): 2.37

Financials

  LLY.N Industry Sector
P/E (TTM): 43.87 37.25 40.68
EPS (TTM): 1.93 -- --
ROI: 7.44 16.52 15.78
ROE: 12.61 17.30 16.82
Search Stocks

Lilly sales inch up on demand for animal health, new drugs

July 23 - Eli Lilly and Co said its quarterly revenue rose about 1 percent, helped by demand for its new cancer and diabetes treatments and the acquisition of Novartis AG's animal health business.

23 Jul 2015

Britain's Immunocore raises $320 mln in record financing round

DUBLIN, July 16 - Britain's Immunocore completed Europe's largest ever financing round by a private life sciences company on Thursday, raising $320 million from investors including Eli Lilly & Co, Malin and Woodford Investment Management.

16 Jul 2015

BRIEF-British biotech firm Immunocore to raise $320 mln in finance

* British biotech firm immunocore says secures $320 million in Europe's largest private life sciences financing

16 Jul 2015

Lilly cancer drug improves survival, raises blood clot risk: FDA

WASHINGTON - Eli Lilly & Co.'s experimental lung cancer drug necitumumab improved overall survival by an average of 1.6 months but also increased the risk of sometimes fatal blood clots, according to a preliminary review by the U.S. Food and Drug Administration.

07 Jul 2015

FDA asks panel to weigh benefit, risk of Lilly lung cancer drug

July 7 - Eli Lilly & Co.'s experimental lung cancer drug necitumumab improved overall survival by an average of 1.6 months but also increased the risk of sometimes fatal blood clots according to a preliminary review by the U.S. Food and Drug Administration.

07 Jul 2015

US STOCKS-Wall St little changed; health stocks rally

* Indexes up: Dow 0.06 pct, S&P 0.13 pct, Nasdaq 0.14 pct (Updates to early afternoon)

25 Jun 2015

New Issue- Eli Lilly prices a triple tranche deal

where assigned, and hit the newskey (F9 on Reuters terminals)

26 May 2015

DIARY-U.S. MEETINGS/WEEK AHEAD

Thomson Reuters April 27, 2015 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - MONTH AHEAD Dividends Non S&P 500 - Weekly Federal Reserve events ConferenceCall/Webcast - Weekly Meetings - Weekly Xtra users can see more details on conference calls & webcasts by hovering your mouse over the RIC, right click, no click on Related Co Data, now click on Co Events.

27 Apr 2015

Lilly profit beats estimates, helped by cost cuts

- Eli Lilly and Co soundly beat quarterly profit estimates on lower-than-expected spending on research and marketing, but revenue slipped as the stronger dollar hurt sales outside the United States.

23 Apr 2015

Lilly profit falls 27 percent, hurt by strong dollar

April 23 - Eli Lilly and Co reported a 27 percent fall in quarterly profit, hurt by a stronger dollar.

23 Apr 2015

Competitors

Earnings vs. Estimates

Search Stocks